NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31

Natera, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$399.42+5.98 (+1.52%)

Close on Oct 19, 2026

Market cap: $57.23B
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$2.31BFY2025, +36.5% a year since FY2013

Where these numbers come from

Parsed from the XBRL in Natera's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NTRA.

Revenue growth37.8% · median 42.7%

Operating margin-10.7% · median 10.9%

Net margin-7.1% · median 9.5%

Company	Revenue	Growth
NTRA	$2.71B	+37.8%
FTRE	$2.68B	-2.1%
GH	$1.18B	+42.7%
CAI	$989.61M	+85.4%
VCYT	$561.90M	+17.3%
BLLN	$397.41M	+90.1%

Company

Next earnings (est.): Nov 5, 2026, after close
Exchange: Nasdaq
Industry: Services-Medical Laboratories
Fiscal year ends: December 31
Employees: 6,140
Held by institutions: 95.2%
Auditor: Ernst & Young LLP
SEC CIK: 1604821

Advertisement
300 × 250